- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
© Adams et al.; licensee BioMed Central Ltd. 2013
Received: 25 April 2012
Accepted: 15 May 2013
Published: 22 May 2013
We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapine, risperidone, or aripiprazole).
Study HBBR was a multicenter, randomized, open-label study comparing the long-term safety and tolerability of LY2140023 with SOC for schizophrenia. Patients had moderate symptomatology with prominent negative symptoms and evidence of functional impairment. Those who met entry criteria were randomized to open-label treatment with either LY2140023 (target dose: 40 mg twice daily [BID]; n = 130) or SOC (n = 131).
There was no statistically significant difference between LY2140023 and SOC for time to discontinuation due to lack of tolerability (primary objective; P = .184). The Kaplan-Meier estimates revealed comparable time to event profiles. Only 27% of LY2140023 and 45% of SOC patients completed the 24-week open-label, active treatment phase. Twenty-seven patients (20.8%) in the LY2140023 group and 15 patients (11.5%) in the SOC group discontinued due to lack of efficacy (P = .044). Twenty-three patients (17.7%) in the LY2140023 group and 19 patients (14.5%) in the SOC group discontinued due to adverse events (physician and subject decision combined, P = .505). The incidence of serious adverse events was comparable between groups. LY2140023-treated patients reported significantly more treatment-emergent adverse events of vomiting, agitation, and dyspepsia, while SOC-treated patients reported significantly more akathisia and weight gain. The incidence of treatment-emergent parkinsonism (P = .011) and akathisia (P = .029) was significantly greater in SOC group. Improvement in PANSS total score over the initial 6 to 8 weeks of treatment was similar between groups, but improvement was significantly greater in the SOC group at 24-week endpoint (P = .004). LY2140023 and SOC groups had comparable negative symptom improvement at 24-week endpoint (P = .444).
These data provide further evidence that the potential antipsychotic LY2140023 monohydrate, with a glutamatergic mechanism of action, may have a unique tolerability profile characterized by a low association with some adverse events such as extrapyramidal symptoms and weight gain that may characterize currently available dopaminergic antipsychotics.
A Long-term, Phase 2, Multicenter, Randomized, Open-label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
ClinicalTrials.gov identifier: NCT00845026.
LY2140023 monohydrate (LY2140023) is an oral methionine prodrug of LY404039, a potent and highly selective agonist for the metabotropic glutamate receptors 2 and 3 (mGlu2/3) [1, 2]. LY2140023 is undergoing testing in clinical trials as a potential treatment for schizophrenia. In a randomized, double-blind, placebo- and active-controlled (olanzapine) clinical trial (HBBD) over a 4-week treatment period, patients receiving 40 mg twice daily (BID) of LY2140023 demonstrated statistically significant improvements in the Positive and Negative Syndrome Scale (PANSS)  total score compared with patients receiving placebo .
The efficacy results in a second, randomized, double-blind, placebo- and active-controlled (olanzapine) clinical trial (HBBI) lasting up to 4 weeks were inconclusive . None of the 4 LY2140023 doses (5 mg, 20 mg, 40 mg, or 80 mg BID) nor the olanzapine dose (15 mg once daily) demonstrated changes different from placebo in the PANSS total score, the primary measure of efficacy. The heightened placebo response in the second phase 2 study likely reduced the ability to detect a significant drug response across the LY2140023 and olanzapine treatment groups.
The safety results from both 4-week, Phase 2 clinical trials comparing LY2140023 with placebo treatment were generally similar. LY2140023 treatment was generally well-tolerated overall and not associated with elevations in prolactin, extrapyramidal symptoms, or weight. However, in the HBBI study, convulsions were reported in 4 patients treated with LY2140023 . This latter finding identified a potentially increased risk of seizures during treatment with LY2140023, but further study is needed to evaluate any potential relationship to duration of exposure.
The current study (HBBR) is the first time patients were assigned to long-term treatment with LY2140023. It is important for assessing any potential association between prolonged duration of exposure to LY2140023 and the incidence of convulsions. The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023 versus those on atypical antipsychotic standard of care (SOC) treatment for up to 24 weeks.
The study included an up to 7-day antipsychotic drug taper/discontinuation phase (Study Period I), a 3-day, single-blind placebo lead-in phase (Study Period II), a 24-week open-label active treatment phase (Study Period III), and an optional 28-week extension phase (Study Period IV). All results pertain to Study Periods I through III only. Patients were randomized to receive either LY2140023 (20, 40, or 80 mg, BID; target dose = 40 mg BID), or SOC (olanzapine [10, 15, or 20 mg, once daily; target = 15 mg/day], aripiprazole [10, 20, or 30 mg, once daily; target = 20 mg/day], or risperidone [2, 4, or 6 mg, once or twice daily; target = 4 mg/day]) treatment. Doses of comparators were based on U.S. labeling. Based upon the available Phase 2 data, an optimal dose of LY2140023 had not yet been identified.
The treating clinician was free to select which SOC antipsychotic to use for each patient randomly assigned to SOC treatment; the clinician was not permitted to switch a patient to another SOC medication once treatment began. Patients randomized to receive LY2140023 were started at a dose of 40 mg BID. For patients randomized to receive SOC treatment, investigators were instructed to begin patients at doses below the target dose for the first 3 days to minimize the potential for adverse events. Dose adjustments, other than the initial scheduled dose titration, were made only if investigators had concerns about patient safety/tolerability or lack of response. Dose decreases to accommodate investigator concern about a patient’s safety or tolerability to study medication could occur at any time, based on the investigator’s clinical judgment; only 1 dose decrease was permitted between visits. Dose decreases for patients receiving LY2140023 should be from 80 mg/day to 40 mg/day (with no intermediate dose). Dose increases to potentially improve clinical response could occur no earlier than Visit 6 (Week 3) to ensure sufficient time for patients to respond, and were made only at scheduled visits. Investigators were permitted to increase the dose for LY2140023 patients to 160 mg/day (80 mg BID), with no intermediate dose. Once patients reached the target dose, dose adjustments for patients on comparator medications could occur in the following increments: olanzapine (+/− 5 mg/day), aripiprazole (+/− 10 mg/day), or risperidone (+/− 2 mg/day).
The primary objective of this study was to assess time to discontinuation due to lack of tolerability, defined as discontinuation due to adverse events, among patients with schizophrenia receiving LY2140023 versus those on atypical antipsychotic SOC treatment for up to 24 weeks. The classification of discontinuation due to adverse events was based on the site investigator’s determination that the primary reason for a patient's early withdrawal from the study was an adverse event.
The secondary objectives of this study included evaluation of the long-term safety, tolerability, and efficacy of LY2140023 compared with SOC treatment. Safety assessments included the incidence of treatment-emergent adverse events (TEAEs), neurological changes, vital signs, laboratory changes, and changes in electrocardiographs and electroencephalographs (EEGs). Extrapyramidal symptoms were assessed by the Barnes Akathisia Scale for akathisia , Simpson-Angus Scale for parkinsonism , and Abnormal Involuntary Movement Scale for dyskinetic symptoms .
All patients had an EEG at baseline and at Weeks 2, 4, 8, 12, and 24 that were evaluated by a single central neurologist. All EEGs were performed on the same model device utilizing the same software and settings.
Efficacy was assessed by the PANSS , CGI-S , and the 16-item Negative Symptoms Assessment (NSA-16) scale . Raters not directly involved with the patient’s treatment were used to assess the PANSS and NSA-16 scales. The raters were blind to the study design, entrance criteria, and treatment assignment; separate raters were used for baseline and endpoint assessments.
All analyses were conducted on an intent-to-treat basis, meaning that data were analyzed by the treatment groups to which patients were randomly assigned, even if the patient did not take the assigned treatment, did not receive the correct treatment, or did not comply with the protocol. No adjustments were made for multiplicity. All treatment comparisons were evaluated based on a 2-sided significance level of 0.05.
Unless otherwise specified, when an analysis of variance (ANOVA) model or an analysis of covariance (ANCOVA) model was used to analyze a continuous efficacy variable, the model contained the main effects of treatment and investigator. Type III sum of squares for the least-squares (LS) means were used for statistical comparison from ANOVA or ANCOVA models.
For the analyses of change from baseline, only patients with a baseline and at least 1 postbaseline measure were included. Unless otherwise specified, baseline was defined as the last nonmissing observation at or before the randomization visit (Visit 3). Endpoint for Study Period III (24 weeks) was defined as the last nonmissing observation obtained from Visit 4 through Visit 13.
The primary safety outcome was the time to discontinuation due to adverse events during Study Period III. Kaplan-Meier estimated survival curves  of time to discontinuation (measured in days) for adverse events were compared between LY2140023 and SOC. The log-rank test was used to compare the LY2140023 and SOC time-to-discontinuation profiles. This study was planned to provide approximately 80% power to detect a hazard ratio of 0.36 in the time to discontinuation due to adverse events over the 24-week active treatment phase of the study.
Secondary efficacy outcomes for the PANSS total and subscores were analyzed using the mixed-model repeated measures (analysis) model (MMRM), with the fixed categorical effects of treatment, gender, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score and baseline-by-visit interaction.
Baseline and demographic characteristics
Baseline and demographic characteristics
(N = 130)
(N = 131)
Age, years, mean (SD)
Gender – female, n (%)
Race, n (%)
American Indian or Alaska Native
Diagnosis, n (%)
Weight, kg, mean (SD)
Age of first episode, years, mean (SD)
Episodes in the last 24 months, mean (SD)
CGI-S, mean (SD)
PANSS total, mean (SD)
PANSS positive, mean (SD)
PANSS negative, mean (SD)
PANSS general psychopathology, mean (SD)
Negative Assessment Scale-16, mean (SD)
The majority of LY2140023-treated patients were taking the targeted dose (40 mg BID) at their final visit of the Study Period (approximate incidence of patients in each dose group at final visit: 14% patients at 20 mg BID; 62% patients at 40 mg BID; and 25% patients at 80 mg BID). The percentage of patients in the SOC group at their final visit of the Study Period receiving the minimum dose was 17%, the targeted dose was 46%, and the percentage receiving maximum dose was 38%. For each drug subgroup within the SOC group, the percentage of patients at their final visit of the study receiving the minimum, targeted, and maximum doses were: OLZ, 20%, 36%, 44%; RIS, 16%, 60%, 24%; and ARI: 14%, 48%, 39%, respectively.
A total of 402 patients entered the study, and 261 patients were randomized to BID doses of LY2140023 (n = 130 patients) or SOC treatment (n = 131 patients); 27% of LY2140023 and 45% of SOC patients completed through the final visit of Study Period III. The most common reasons for study discontinuation among patients in both treatment groups were perceived lack of efficacy, adverse events, and withdrawn consent. Twenty-seven patients (20.8%) in the LY2140023 group and 15 patients (11.5%) in the SOC group discontinued due to lack of efficacy (physician and subject decision combined; P = .044). Twenty-three patients (17.7%) in the LY2140023 group and 19 patients (14.5%) in the SOC group discontinued due to adverse events (physician and subject decision combined, P = .505).
Primary objective – time to discontinuation due to adverse events
However, time to discontinuation for any reason (p = .002) was significantly shorter for patients in the LY2140023 group than for those on SOC (data not shown).
Other safety measures
A total of 30 patients (LY2140023, n = 18; SOC, n = 12) experienced at least 1 serious adverse event (SAE) during the 24-week active-treatment phase of the study. The incidence of SAEs was not significantly different between groups. Reported SAEs included 3 deaths: 2 were in patients randomized to LY2140023, and 1 was in a patient who had not yet received any study drug. None of the 3 deaths was considered by investigators to be related to treatment with study drug or to protocol procedures.
One patient experienced 2 convulsions 1 day after discontinuing LY2140023 (approximately 3 weeks after randomization) and initiating treatment with intramuscular haloperidol; the convulsions were reported as possibly related to LY2140023 treatment. Another patient experienced a convulsion during the placebo lead-in phase; this convulsion was reported as possibly related to protocol procedure.
SAEs commonly reported (≥1% of LY2140023 patients) in the LY2140023 group were schizophrenia, psychotic disorder, agitation, insomnia, and pneumonia. Among patients in the SOC group, common SAEs were schizophrenia and psychotic disorder.
Treatment-emergent adverse events at incidence ≥5% in the LY2140023 group, or significantly different between groups
Event, n (%)
(N = 130)
(N = 131)
Patients with ≥ TEAE
Blood CPK increases
Within-group comparisons revealed a significant reduction from baseline to last observation in fasting cholesterol (−0.30 mmol/L, P < .001), LDL cholesterol (−0.28 mmol/L, P < .001), and triglycerides (−0.11 mmol/L, P = .008) in patients treated with LY2140023, and a significant decrease in HDL cholesterol (−0.06 mmol/L, P = .004) in patients treated with SOC. There was a mean decrease in LDL cholesterol in the LY2140023 group that was significantly greater than the decrease observed in the SOC group (P = .031), and a decrease in the level of triglycerides in the LY2140023 group versus an increase in the SOC group (P = .008). The mean decrease (−0.06 mmol/L) in HDL cholesterol observed in the SOC group was significantly different from the slight increase (0.01 mmol/L) observed in the LY2140023 group (P = .018). A significant reduction from baseline was also observed for prolactin (−4.33 μg/L, P = .003) in the LY2140023 group, although prolactin changes did not differ between the groups (P = .062). There were no other clinically significant differences in mean laboratory values between treatment groups.
Within-group comparisons showed significant increases in weight at every visit for patients in the SOC group (maximum increase: 3.12 kg, P < .001), while LY2140023-treated patients had significant decreases in weight at Weeks 12, 16, and 24 (maximum decrease: -2.04 kg, P < .05). Pairwise comparisons revealed significant differences in mean weight change between LY2140023- and SOC-treated patients at every visit. Significantly more patients in the SOC group met potentially clinically significant (PCS) criteria of an increase in weight of at least 7% from baseline to endpoint (SOC, 21.4%, n = 28; LY2140023, 8.2%, n = 10; P = .004), while significantly more patients in the LY2140023 group met PCS criteria for decreased weight (SOC, 2.3%, n = 3; LY2140023, 14.8%, n = 18; P < .001).
Within-group comparisons showed a mean reduction from baseline in the Barnes Akathisia Scale global score for akathisia at most visits in the LY2140023 group (P < .05), while changes from baseline in the SOC group generally did not reach significance. Both treatment groups had statistically significant, within-group improvements on the Simpson-Angus Scale total score for parkinsonism at each visit (P < .001, most visits). There were few statistically significant differences observed from baseline to postbaseline visit in the Abnormal Involuntary Movement Scale total score for dyskinetic symptoms within either treatment group. Pairwise comparisons revealed few statistically significant differences between the LY2140023 and SOC treatment groups across these 3 extrapyramidal symptom measures (data not shown). The overall incidence of treatment-emergent parkinsonism (SOC, n = 14; LY2140023, n = 3; P = .011) and akathisia (SOC, n = 18; LY2140023, n = 6; P = .029) was significantly higher among patients treated with SOC than among patients in the LY2140023 group.
Comparisons of changes in electrocardiogram intervals and heart rate did not show significant differences between groups that were clinically significant.
There were no clinically significant differences in baseline EEG scores between groups and no clinically significant changes in postbaseline EEG scores. Abnormal epileptiform-like changes were not frequent or remarkably different between treatment arms (LY2140023, 0%; SOC, 3.4%).
Patients in both treatment groups showed a statistically significant within-group mean reduction in the PANSS negative subscore at all visits, with no significant differences observed between the LY2140023 and SOC treatment groups (data not shown). Similarly, patients in both treatment groups showed statistically significant within-group mean improvement in the NSA-16 scale, with no significant between-group differences (Figure 3B).
Patient compliance with study medication was assessed at each visit by direct questioning and by counting returned tablets. Patients in both treatment groups showed relatively high compliance rates with no between-group differences (mean percentage study drug compliance: SOC, 88%; LY2140023, 87%; P = .539).
There were no statistically significant differences in the incidence of concomitant use of any class of medication (benzodiazepines/hypnotics/anxiolytics, antidepressants or mood stabilizers, anticholinergic agents, or other therapies) observed between the treatment groups during the active treatment period. Approximately half of patients in this study reported the use of at least 1 concomitant benzodiazepine anxiolytic, or hypnotic agent.
This study was a multicenter, randomized, open-label, phase 2 clinical trial designed to evaluate the long-term safety and tolerability of LY2140023 monohydrate (LY2140023) in moderately ill patients with schizophrenia who had prominent negative symptoms and evidence of functional impairment. The primary analysis showed LY2140023 to be comparable to SOC in time to discontinuation due to lack of tolerability through 24 weeks of treatment. There were no significant differences between treatment groups in the incidence of SAEs, TEAEs, or adverse events leading to study discontinuation. However, a significantly greater number of patients in the LY2140023 group discontinued from the study due to perceived lack of efficacy compared with those in the SOC group. In addition, time to discontinuation for any reason was significantly shorter for patients in the LY2140023 group than for those on SOC. All treatments in the study were generally well-tolerated.
The safety findings from this 24-week study were generally consistent with observations from the 2 previous, 4-week clinical trials. In these acute trials, LY2140023-treated patients generally did not differ significantly from placebo-treated patients with regard to prolactin elevation, extrapyramidal symptoms or weight gain, while comparisons between placebo and olanzapine revealed weight gain and limited or no reduction in prolactin in the olanzapine-treated patients. In the current study, LY2140023 treatment was characterized not only by a decrease in mean weight over 24 weeks, as compared with an increase observed with SOC treatment, but also by improvement across various metabolic parameters. LY2140023 was associated with a reduction in akathisia, and with less treatment-emergent akathisia and parkinsonism as compared with SOC treatment. This unique tolerability profile highlights possible advantages of a glutamate-based schizophrenia therapy versus dopaminergic-based therapies.
The occurrence of convulsions within the 4-week HBBI study identified a potentially increased risk of seizures during treatment with LY2140023, warranting further study following long-term exposure. In the current study, there were 2 patients who experienced convulsive events, 1 patient treated with LY2140023 and a second patient treated with placebo prior to randomization. The overall LY2140023 exposure-adjusted rate of seizures had decreased substantially with the increased compound exposure in the current 24-week HBBR study and in other ongoing studies. Extensive repeat EEG assessments did not demonstrate any abnormal epileptiform-like changes that were frequent nor remarkably different between treatment arms. Study results do not suggest an increased risk of seizures following long-term exposure. Based on results of the current study, the safety profile of LY2140023 appears similar after short- and long-term exposure.
Efficacy was a secondary endpoint in this study. Improvement on the PANSS total score and most other measures of efficacy over the initial 6 to 8 weeks of treatment did not differ between treatments, while improvement at later time points was significantly greater in the SOC group compared with LY2140023. The mean PANSS visit response results were likely impacted by the rate of early discontinuation and the treatment-group difference in discontinuation due to lack of efficacy. A post hoc analysis of only the patients who had PANSS data at the last visit demonstrated similar improvement in the SOC group and the LY2140023 group, although there were significantly more patients with final visit PANSS scores in the SOC group (data not shown). LY2140023 and SOC had comparable negative symptom improvement over the 24 weeks. Further investigation of the efficacy of LY2140023 in the treatment of schizophrenia utilizing placebo-controlled study is warranted.
This study was an open-label study without a placebo treatment arm, preventing definitive conclusions regarding efficacy. This specific design element (that is, open-label) was chosen in order to closely monitor the safety of patients in this initial long-term study. In addition, investigators selected the SOC treatment to be used for each patient in the SOC treatment group, and given the knowledge available for these marketed drugs, SOC treatment may have been optimized by clinicians to a greater extent than for treatment with LY2140023. Normal EEGs were required at baseline, and therefore, any safety results regarding seizures may be limited by this less generalizable population. Similarly, this study focused on moderately ill patients with schizophrenia who had prominent negative symptoms and evidence of functional impairment, and therefore the data are primarily generalizable to patients with a similar symptom profile. Lastly, the overall relatively high discontinuation rate (64%) may limit inference of results on outcome scales.
This was the first clinical study to examine the long-term safety of a metabotropic glutamate receptor agonist, a potential new therapeutic agent in the treatment of schizophrenia. LY2140023 was comparable to atypical SOC medications in the primary analysis of time-to-discontinuation due to adverse events, a finding demonstrating that LY2140023 was generally well-tolerated over clinically relevant treatment duration. Similar to previous acute studies, LY2140023 had a distinct safety profile characterized by a low incidence of dopamine-related adverse events and a decrease in mean weight compared with SOC treatment.
The following institutional review boards provided ethical approval for the study: Med. Ethikkommission II Fakultät Für Klin. Medizin Mannheim, Comité de Educación Médica, Grupo Ángeles, Centro Para Las Adicciones Y Salud Mental Hidalgo, Hospital Psiquiátrico Estatal, Comité Provinicial de Bioética, CIF-Biotec, Hospital Civil De Guadalajara, Bekhterev Psychoneurological Institute, Mental Health Research Centre of Russian, Serbsky National Research Center, Lipetsk Regional Psychoneurological Hospital #1, National Ethics Committee, Moscow Research Institute of Psychiatry, St. Anthony Hospital Institutional Review Board, Western Institutional Review Board, IU Institutional Review Board.
This study was supported by Eli Lilly and Company, Indianapolis, Indiana, USA. We would like to acknowledge editorial assistance from Angela Lorio, ELS (PharmaNet/i3, an InVentiv Health Company).
Presented at the 13th International Congress on Schizophrenia Research (ICOSR): Kinon BJ, Adams DH, Baygani S, et al. A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia. Schizophr Bull (2011) 37 (suppl 1): 311.
- Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD: Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (−)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2007, 321: 308-317. 10.1124/jpet.106.110809.View ArticlePubMedGoogle Scholar
- Schoepp DD, Marek GJ: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Curr Drug Targets CNS Neurol Disord. 2002, 1: 215-225. 10.2174/1568007024606177.View ArticleGoogle Scholar
- Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276. 10.1093/schbul/13.2.261.View ArticlePubMedGoogle Scholar
- Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007, 13: 1102-1107. 10.1038/nm1632.View ArticlePubMedGoogle Scholar
- Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N, HBBI Study Group: A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011, 31: 349-355. 10.1097/JCP.0b013e318218dcd5.View ArticlePubMedGoogle Scholar
- American Psychiatric Association: Text Revision (DSM-IV-TR). Diagnostic and Statistical Manual of Mental Disorders. 2000, Arlington, VA: American Psychiatric Publishing, Incorporated, FourthGoogle Scholar
- Guy W: Revised (Publication ADM 76–338). ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, Md: US Dept of Health, Education, and Welfare, 218-222.Google Scholar
- Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry. 1989, 154: 672-676. 10.1192/bjp.154.5.672.View ArticlePubMedGoogle Scholar
- Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970, 212 (Suppl): 11-19.View ArticleGoogle Scholar
- Guy W: Revised (Publication ADM 76–338). ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, Md: US Dept of Health, Education, and Welfare, 534-537.Google Scholar
- Alphs LD, Summerfelt A, Lann H, Muller RJ: The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989, 25: 159-163.PubMedGoogle Scholar
- Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/13/143/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.